![Roupen Odabashian: The evolution of diagnostic testing](https://oncodaily.com/pub/uploads/2024/07/Untitled3.png)
Roupen Odabashian: The evolution of diagnostic testing
Roupen Odabashian shared a post on LinkedIn about a recent paper by Robert Avram et al. titled “AI-RISE to the Challenge — Artificial Intelligence Reduces Time to Treatment in STEMI” published in NEJM AI.
Authors: Robert Avram and William Fearon
Roupen Odabashian commented on LinkedIn sharing this paper:
“The evolution of diagnostic testing
In the 1900s, when there were not many diagnostic tests available, physicians relied heavily on physical exams. They were very good at it; their ears could catch the faintest heart murmurs, and their fingers could feel many spleens or enlarged livers.
However, with the development of more sophisticated diagnostic tests, the use of physical exams decreased, and we started relying heavily on diagnostic tests.
Our diagnostic accuracy is not comparable to that of a CT scan or an Echo, and this is part of evolution. As human beings, we advance and make better tools.
This study, published in NEJM AI, is an example of how AI can help identify signs of heart artery blockage that require emergent intervention faster than the traditional standard of care.
These minutes of faster intervention are crucial for a dying heart muscle gasping for oxygen. Cardiologists are still required in this case because they are the ones who perform the procedure and intervene on the patient.”
Source: Roupen Odabashian/LinkedIn
Dr. Roupen Odabashian is an Internal Medicine Physician and Hematology/Oncology Fellow at the Karmanos Cancer Institute and is actively involved in pioneering cancer treatments and conducting clinical research.
In addition, he hosts a podcast at OncoDaily, engaging with leading experts in oncology to share valuable insights with the medical community. Dr. Odabashian also contributes his expertise as an advisor at Spiraldot Health and Mesh AI.